newsletter published in partnership between
TMIC and the Metabolomics Society
Issue 31 - March 2014
Metabolomics Society News
Adjunct Professor, Head of the Metabolomics Unit, FIMM Technology Centre, Institute for Molecular Medicine Finland, Helsinki, Finland
Dr. Vidya Velagapudi obtained her Ph.D in Applied Biochemistry from University of Saarland in collaboration with the Max-Planck Institute for Informatics, Saarbrucken, Germany in 2005. Later on Dr. Velagapudi moved to VTT Technical research centre of Finland as a post-doctoral fellow and continued as a Research Scientist and Project Manager during 2006-2009. In 2010, Dr. Velagapudi has taken up the role as Head of the Metabolomics Unit at Institute for Molecular Medicine Finland (FIMM), a Nordic EMBL partner institute. From 2012 onwards Dr. Velagapudi is also affiliated with the University of Helsinki as an Adjunct Professor teaching clinical metabolomics. Dr. Velagapudi has been acting as editorial board member and reviewer for several international journals in the field of metabolomics.
|This section is
Increasingly, researchers are relying on metabolomics to uncover sensitive disease biomarkers. In this paper, the investigators utilized metabolomic profiling to identify colorectal cancer (CRC) biomarkers. Using gas chromatography-Time-of-Flight mass spectrometry (GC-TOFMS), they sought to identify metabolite markers that would allow them to differentiate between CRC and non-CRC specimens. They analyzed 376 surgical specimens from CRC patients from hospitals in China and the US. As a result of this study, they identified a panel of 15 significantly altered metabolites. Despite the fact that samples were from different geographical locations, they shared a common metabolic signature with great prognostic potential.
Major depressive disorder (MDD) is a debilitating and widespread mental disorder. There is a need for reliable biomarkers for the diagnosis of MDD. In this study, the researchers used gas chromatography-mass spectrometry (GC-MS) to analyze urine samples from 126 MDD and 134 healthy subjects. Combined with orthogonal partial least-squares discriminant analysis (OPLS-DA), they identified 23 urine metabolites that allowed them to differentiate between the two patient groups. The research team narrowed the candidate diagnostic metabolites for MDD from 23 down to 6 (sorbitol, uric acid, azelaic acid, quinolinic acid, hippuric acid, and tyrosine). By adding a previously identified urine biomarker (N-methylnicotinamide), they were able to increase the accuracy of the biomarker panel. This work represents a promising start to the development of a urine-based diagnostic test for MDD.
|26 Feb 2014
Understanding the fundamental metabolic workings of a cell in a changing environment
Fungal geneticist Scott Baker rifles through a stack of petri dishes housed in a small refrigerator at EMSL. He selects a plate dotted with white cauliflower-shaped colonies of fungus, punctuated by one brazen smudge that stands out from the rest. "This one is red. Not sure why," Baker says.
Each colony on the plate is a different mutant of Yarrowia lipolytica, an oil-producing yeast that Baker and his collaborators at MIT, UCLA and Sweden's Chalmers University hope to coax into pumping out biofuel. The small room where the mutants reside contains only basic equipment for growing and looking at the microbes. But Baker, the Science Theme Lead for Biosystem Dynamics and Design at EMSL, knows that just down the hall a whole slough of instruments awaits the mutants. "This is only the staging area," Baker says.
Metabolomics may have a long way to go before it catches up to proteomics, Metz says, but EMSL's progress is in full swing. The world-class mass spectrometry facility that has driven EMSL's leadership in proteomics is now being tweaked to accommodate metabolomics as well. Chemists in the NMR facility are developing methods to sample living cultures as they grow, and systems biologists are employing supercomputers to run simulations of the metabolic cycles that drive the cell. Metz and his colleagues are in the throes of developing a custom metabolomics facility that will unite many of these diverse capabilities into a common space, streamlining experiments and giving top priority to users interested in metabolomics
"The Holy Grail in all of these 'omics approaches is to make a predictive model of how the cell works, and we're still a long way from doing that," says EMSL scientist and PNNL Laboratory Fellow H. Steven Wiley. "The whole idea about systems biology is to understand how the whole organism works so you can engineer it. To do that you really need a predictive model, and you need a way to test the model. And unless you can measure a lot of the metabolites and intermediates, there's no way you can test these predictive models."
The challenges of metabolomics may be vast, but EMSL scientists, users and collaborators are all in.
The Yarrowia lipolytica biofuels project, funded by the Department of Energy's Office of Biological and Environmental Research, is a prime example of how scientists will draw on several techniques to yield metabolomics results. For most of the samples the team analyzes, a simple methanol/chloroform extraction can transform one "tube of goo" (as Metz puts it) into three layers, each containing its own unique slurry of compounds: polar metabolites (such as carbohydrates, amino acids and some vitamins), lipids or proteins. Each of these layers can then be analyzed using specialized instruments to get a snapshot of cellular metabolism.
The polar metabolites, which rise to the top, are amenable to analysis by gas chromatography coupled with mass spectrometry, or GC-MS. "GC-MS is one of the best methods for identifying polar metabolites with high confidence," says Metz, who specializes in mass spectrometry and participates in the Yarrowia project with Baker. As opposed to liquid chromatography, in which molecules interact with both the column and liquid mobile phase in various (and sometimes mysterious) ways, GC requires a chemical derivatization step that levels the playing field. Once derivatized, the molecules interact with only the GC column in a consistent way, yielding a reproducible separation together with a mass spectrum that can be compared between instruments at different facilities. This consistency has yielded the construction of useful GC-MS spectral reference libraries that scientists can use to identify chemical species in a mixture. Metz often draws on Agilent's library, which contains both retention indices and mass spectra for 700 metabolites.
The ultimate goal of the Yarrowia project is to coax the microbe to produce biofuels in the form of lipids such as triacylglycerides. The yeast shunts lipids into storage chambers called "lipid bodies," and project scientists plan to analyze the types of lipids produced in response to different environmental and genetic modifications. But complex lipids aren't amenable to analysis by GC-MS (or NMR), so the lipid fraction of each sample gets analyzed by liquid chromatography-MS. Unfortunately, reference libraries of lipids don't exist to the same extent as those for polar metabolites amenable to GC-MS. So PNNL scientists are in the process of putting together their own lipid library. "We must rely on MS data to inform us what the most likely identification is, then we pick the corresponding retention time and m/z and put it in the database," Metz says. This "lipidomics" capability is a major contribution PNNL scientists are making to the greater Yarrowia project, which spans multiple institutions and incorporates genomics, computational models and eventually re-engineering of the microbe.
Meanwhile, Baker takes different approaches to study the movement of lipids throughout yeast cells. Drawing on flow cytometry, microscopy and MS imaging techniques, Baker's team analyzes how lipid storage changes with yeast development. "We would like to see metabolomics go beyond just the 'omics part," Baker says. "We want to see metabolomics in time and space." That means looking at the way metabolites get shuttled in between different compartments of the cell, and in between different microbes in a community. Understanding metabolism on both an intra- and intercellular level will be a necessary step in engineering microbes to produce certain products. After all, Baker says, "We're asking a lot of these microbes."
|18 Feb 2014
Patti wins Sloan Research Fellowship
The Alfred P. Sloan Foundation announced Feb. 17th that WUSTL’s Gary Patti has been awarded a 2014 Sloan Research Fellowship. He is among 126 outstanding U.S. and Canadian researchers selected as fellowship recipients this year. Awarded annually since 1955, the fellowships are given to early-career scientists and scholars whose achievements and potential identify them as rising stars, the next generation of scientific leaders.
“For more than half a century, the Sloan Foundation has been proud to honor the best young scientific minds and support them during a crucial phase of their careers when early funding and recognition can really make a difference,” said Dr. Paul L. Joskow, President of the Alfred P. Sloan Foundation. “These researchers are pushing the boundaries of scientific knowledge in unprecedented ways.”
” I am pleased and excited that Gary has been named a Sloan Fellow,” said William Buhro, PhD, professor and chair of chemistry. “Patti is a pioneer in the rapidly developing field of metabolomics, in which the wide arrays of small-molecule metabolites in biological systems are profiled. Metabolomics presents a massive data-analysis challenge, to which Gary is contributing new technologies. He is also applying his new metabolomics technologies to study the biochemistry of disease states, which will advance medical therapies.”
“The goal of metabolomics is to take a urine, blood or tissue sample, analyze it with an instrument called a mass spectrometer, and acquire a complete profile of all of the small molecules in the sample,” said Patti, PhD, assistant professor in the departments of chemistry, genetics and medicine. The profile might reveal whether the sample donor is ill, at risk of developing a disease, has been exposed to a toxin, or is unable to tolerate a drug therapy.
Metabolomics has already provided unparalleled insight into previously opaque illnesses, such as chronic pain. “We identified a molecule that, prior to our studies, was not known to be a naturally occurring compound. We have demonstrated that this molecule is an important player in mediating chronic pain, and this has opened up new avenues for therapies that could help millions of people,” Patti said.
His lab is also hot on the trail of sarcopenia, the muscle wasting that occurs in some elderly patients and leads to “frailty” that has also resisted scientific inquiry in the past. They identified six small molecules associated with aging in Caenorhabditis elegans, a worm that scientists use as a model system. Two of these compounds change as a function of age in healthy human skeletal tissue and may be involved in sarcopenia. In the meantime the group is establishing a library of metabolite levels in long-lived model organisms.
Past Sloan Research Fellows include physicist Richard Feynman and game theorist John Nash. Since the beginning of the program in 1955, 42 fellows have received a Nobel Prize in their respective field, 16 have won the Fields Medal in mathematics, 13 have won the John Bates Clark Medal in economics, and 63 have received the National Medal of Science.
Scientists in eight scientific and technical fields—chemistry, computer science, economics, mathematics, evolutionary and computational molecular biology, neuroscience, ocean sciences, and physics—are eligible for the awards.
The fellowships are awarded through close cooperation with the scientific community. Candidates must be nominated by their fellow scientists, and winning fellows are selected by an independent panel of senior scholars on the basis of a candidate’s independent research accomplishments, creativity, and potential to become a leader in his or her field.
|17 Feb 2014
US launch carries great expectations
CORK firm Metabolomic Diagnostics is preparing to launch the world’s first test for pre-eclampsia in early pregnancy on the US market next year.
The long-term aim is to sell the test to every country in the world and the expectation of company founder and chief executive Charles Garvey is that the company could earn revenues of tens of millions of euro within five years.
Set up to commercialise technology developed at UCC, Metabolomic Diagnostics is based at Little Island, where it employs a team of five scientists.
Participating in a €6m EU-funded research project on biomarkers in pregnant women, the company raised venture capital funding of €750,000 last month, which is being used to advance commercialisation of the research.
According to Mr Garvey, the pre-eclampsia test has the potential to transform maternal and fetal care globally, improving quality of care and reducing costs.
“Between 70,000 and 80,000 women die every year from pre-eclampsia and around 500,000 infants die annually as a direct result of the condition,” he reveals.
The commercial potential of the test is indicated by the fact that in the US alone, $7bn (€5.1bn) is spent annually on prenatal care associated with pre-eclampsia.
The formation of Metabolomic Diagnostics came about as a result of an introduction which took place through the Enterprise Ireland Business Partners programme.
Mr Garvey, a serial entrepreneur with experience in growing Irish technology companies internationally, met UCC professor of obstetrics Louise Kenny, who had been researching pre-eclampsia since 2007.
He saw global potential in the early detection test she had been working on.
“The company was set up in 2011 specifically to license the research which had been patented by UCC,” says Mr Garvey, who was joined by two other experienced entrepreneurs, Paul Hands and Diarmuid Cahalane in establishing the new venture.
Prof Kenny, who was awarded an Enterprise Ireland Life Science & Food Commercialisation award for developing the test, became a member of the company’s advisory board.
Since 2011 the company’s researchers have been involved in validating the research and commercialising the test. Participation in the EU study will provide the firm with blood samples from 5,000 pregnant women to assist in this work.
In December last year the company secured €750,000 through a syndicate of investors, which included SOSventures Ireland Fund, AIB Seed Capital Fund and Enterprise Ireland — which had identified Metabolomic Diagnostics as a High Potential Start-Up in 2013.
Mr Garvey expects the first version of the test, which is called PrePsia, to be ready for launch in the US market in 2015.
“We have chosen to launch in the US first because of its population size and the market spend,” he says, explaining that many life-science companies start with a US launch.
The aim is to partner with a major US laboratory, which will help speed up the process of getting regulatory approval for the new test there. Getting regulatory approval for every country is a time-consuming and expensive process.
“It makes sense to start with a market with a population of 310m. We can use revenues generated in the US market to help fund the roll-out in other countries.”
Mr Garvey has already had discussions with potential US partners and has engaged with the Food and Drugs Administration.
He says the company has also looked at regulatory requirements in other markets with a view to expanding.
In the future, it hopes to develop tests to detect other complications of pregnancy such as gestational diabetes, pre-term delivery and underdeveloped foetuses.
For now, the focus is on finalising the research and producing the first version of the test in readiness for commercial launch.
Source: Irish Examiner
|2 March 2014
Metabolomics course at the upcoming Pittcon
information, please visit the Pittcon
|4 March 2014
Bruker Metabolomics Canada
Spring Tour 2014
Coffee, and the Resulting Effects:
Combining food with clinical
metabolomics based on high resolution
GC-MS and LC-MS
Metabolomics is an integral part of the whole OMICS picture. In the final step of the omics cascade, the metabolome changes as a result of the genome, transcriptome and proteome. These changes in the small molecule profile most closely express the phenotype. In consequence, metabolomics has gained major attention in human health, food and nutrition, and many other diverse areas of research. This presentation will cover several topics of interest to food and clinical researchers, based on high resolution LC-MS and GC-MS analysis.
The first is on the intensity of coffee blends as determined by the concentration of specific small molecules. The second describes a diabetes biomarker research study in which the identification of a single metabolite explained an unexpected trend in the data. Finally, in food authenticity, whisky types correlated with geographic regions.
The typical workflow involves 1) non-targeted profiling using high resolution LC-MS or GC-MS; 2) differentiation of the profiles by statistics; 3) identification of sources of grouping and differentiation; followed by 4) validation of putative biomarkers using targeted approaches.
In particular, the identification of the sources of grouping and differentiation will be discussed. Compounds analyzed by LC-MS were tentatively identified by generating unique molecular formulas, based on accurate mass and isotopic patterns. Subsequent in-silico fragmentation and exploration generated single candidate structures. The reliable identification of these compounds saved analysis time and the acquisition of multiple reference materials to confirm the identity of the target compounds.
Metabolomics: Applications to Human
Disease, Food and Botanicals
Applications for Food Science
The latest revolution in microbiology uses MALDI-TOF mass spec. Bacteria and fungi are identified within minutes, frequently to the species level. There are many other applications with the same technology.
additional applications include:
presentation will introduce you to current
technologies from Bruker, the world leader
in MALDI systems that are driving these
application. You will see examples of the
most common applications as well as have
an opportunity to learn more in a question
and answer round-table discussion
following the presentation.
|6 March 2014
MzTab for Metabolomics
|17-21 Mar 2014
EMBO Practical Course on
Metabolomics Bioinformatics for Life
This course will provide an overview of key issues that affect metabolomics studies, bioinformatics tools, and procedures for the analysis of metabolomics data. It will be delivered using a mixture of lectures, computer-based practical sessions and interactive discussions. The course will provide a platform for discussion of the key questions and challenges in the field of metabolomics.
This course is aimed at PhD students and researchers with a minimum of one year’ s experience in the field of metabolomics who are seeking to improve their skills in metabolomics data analysis. Participants must have experience using R (including a basic understanding of the syntax and ability to manipulate objects) and the UNIX/LINUX operating system.
For more information, visit http://www.ebi.ac.uk/training/course/metabolomics-2014.
|18-21 Mar 2014
Singapore Lipid Symposium
The Singapore Lipid Symposium (biennial, since 2006) has rapidly evolved into a key event to keep up to date for novel developments in lipidomics in Asia Pacific. Based on past experience, we are expecting participation of approximately 150-200 from around the world and representation from a wide range of areas in the life sciences across academia and industry. The official launch of a new network dedicated to deciphering lipidomics variations will be a major first highlight, followed by community building workshops and the main symposium session.
For more details, please visit http://www.lipidprofiles.com/index.php?id=82
|19 Mar 2014
Prospects and Pitfalls in
Metabolomics: From Study Designs to
Interpreting Data in Biomedical Applications
In this web seminar, Professor Oliver Fiehn of UC Davis will explain the importance of different steps in the metabolomic workflow and how to avoid the most dramatic pitfalls along the way. Key topics covered will include defining a suitable hypothesis, designing a study, preparing biological specimen for comprehensive chemical analysis, choosing the most suitable analytical platforms, analyzing raw data including identification of metabolites, using quality controls and validations, and interpreting the data on the background of biomedical questions. Examples will be given from published work using blood plasma in human cohort studies and animal models.
LCGC and Spectroscopy
Prof. Oliver Fiehn, PhD
Director, West Coast Metabolomics Center
UC Davis Genome Center
University of California, David
IMPORTANT - PLEASE READ
This is a FREE streaming audio Webcast and does not require a phone line. If you have any questions regarding this Webcast, please contact Kristen Moore, firstname.lastname@example.org.
Register for this FREE Webcast!
For details, visit the event website.
|7-11 Apr 2014
Workshop Metabolomics 2014
|30 Apr 2014
Analytical Tools for
Cutting-edge Metabolomics - a joint meeting of
the Analytical Division of the RSC and the
international Metabolomics Society
Analytical chemistry has been one of the driving forces behind the development of metabolomics research over the past decade. The conference will bring together exceptional scientists for a program consisting of plenary and invited talks, posters, as well as an oral session devoted to early career researchers. It will be an excellent opportunity for analytical chemists to learn more about metabolomics and its application, and for metabolomics scientists to improve their knowledge of cutting-edge bioanalytical tools.
Deadline for submission of abstracts: 14 March 2014
Prof. Jeremy Nicholson, Imperial College, London UK - Plenary speaker
Dr Julian Griffin, MRC Human Nutrition Research, Cambridge, UK
Prof. Roy Goodacre, University of Manchester, UK
Prof. Jean-Luc Wolfender, University of Geneva, Switzerland
Dr Steffen Neumann, Leibniz Institute of Plant Biochemistry, IPB Halle, Germany
Prof Paul Thomas, Loughborough University
|19-21 May 2014
8e Journées Scientifiques
du Réseau Français de Métabolomique et
The Amiens RFMF Congress (7 JS RFMF) took place in 2013 due to the generous support of Picardie Jules Verne University and various corporations. This event featured three keynote speakers, Age Smilde, Amsterdam, The Netherlands; Joachim Kopka, Golm-Postdam, Germany and Reza Salek, Cambridge, UK presenting state-of-the-art topics for metabolomics. This event was very successful, with 162 attendees from 75 public and private laboratories, 59 high-quality scientific presentations, 4 workshops and 6 industrial seminars. Four conferences, one workshop and one industrial seminar were held in English. The 2013 event gave an opportunity to gauge the strength and dynamic qualities of the French or French-speaking metabolomics and fluxomics community.
The 8th RFMF Congress will take place in Lyon (Eastern France) in May 19-21, 2014. The Metabolomic Community of the Lyon and Rhône-Alpes Region laboratories is the local organizer of the 2014 edition.
The key topics, chosen by Lyon metabolomics community, for the 8th RFMF Congress are:
The 8th RFMF Congress will include several workshops, one of them dealing with the Galaxy platform (workflow for metabolomics), one dealing with “Sample preparation for metabolomics study”, and a third one with “MetaboLights and COSMOS initiative”.
RFMF is generously supporting the attendance of students or post-docs (under 35 years old) at The 8th RFMF Congress Lyon 2014 through the provision of travel grants (up to €1000 for overseas applicants).
For more information on the 8th RFMF Congress, please visit https://colloque.inra.fr/8_js_rfmf_lyon_2014
|22-23 May 2014
Metabolomics Conference -
Advances & Applications in Human Disease
Special offer for Metabolomics Society Members and MetaboNews Subscribers:
Receive 30% off Registration with discount Code: meta30
For more information, see the event flyer or visit http://www.gtcbio.com/conference/metabolomics-overview
|16-17 Jun 2014
Informatics and Statistics
for Metabolomics (2014)
A poster announcing this workshop can be found here.
The workshop will cover many topics ranging from understanding metabolomics technologies, data collection and analysis, using pathway databases, performing pathway analysis, conducting univariate and multivariate statistics, working with metabolomic databases and exploring chemical databases. Participants will be given various data sets and short assignments to assist with the learning process.
This course is intended for graduate students, post-doctoral fellows, clinical fellows and investigators who are interested in learning about both bioinformatic and cheminformatic tools to analyze and interpret metabolomics data.
Prerequisite: Your own laptop computer. Minimum requirements: 1024x768 screen resolution, 1.5GHz CPU, 1GB RAM, recent versions of Windows, Mac OS X or Linux (Most computers purchased in the past 3-4 years likely meet these requirements). If you do not access to a laptop, you may loan one from the CBW. Please contact email@example.com for more information.
Pre-Readings: You are expected to have completed the following tutorials in R beforehand. The tutorial should be very accessible even if you have never used R before. Please complete the following: R Tutorial
|23-26 Jun 2014
Metabolomics 2014: 10th
Annual International Conference of the
We are delighted to host the 10th Anniversary of the International Conference of the Metabolomics Society (Metabolomics2014) at Keio University in Tsuruoka City, where the very first meeting of the society was held in 2005. Since then, Tsuruoka has grown to “a city of metabolomics”; various additional research buildings have been built, and two spin-out companies established. Tsuruoka is a pretty city located 500 km north of Tokyo (about 1 hour flight), and surrounded by beautiful Japanese nature, historic spots, and exotic culture. You will also enjoy the best authentic Japanese food and sake (rice wine), as well as hot springs. So, come celebrate the 10th anniversary of the society, and enjoy high-quality scientific presentations by top-notch researchers around the world.
Early registration and abstract submission due March 31, 2014.
For detailed information about Metabolomics 2014, visit http://metabolomics2014.org.
|10-12 Sep 2014
Call for Papers
If you would like to be considered for an oral presentation at this meeting, Submit an abstract for review now!
Oral Presentation Submission Deadline: 31 January 2014
Call for Posters
You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 27 August 2014
Drug Discovery and Pharma
Human Health and Nutrition
Microbial, Invertebrate and Environmental Applications
Data Analysis and Integration with Systems Biology
For more details, please visit the conference website.
|29-30 Oct 2014||
Clinical Applications of
As the analytical power of mass spec is realised, the range of applications using this technology continues to expand. Focus at this meeting will be given to both traditional & emerging uses of MS in the clinic. Hot topics to be covered include developments of MS in applications ranging from vitamin D detection to newborn blood spot analysis. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to build new relationships and optimise your workflow.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Food Analysis Congress, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=CAMS2014
|29-30 Oct 2014
Food Analysis Congress
Focus will be given to advances in both the analysis of natural food allergens and toxins, as well as contaminants introduced through processing and packaging. Points for discussion will also include the ongoing issue of food traceability and efforts to reduce food fraud. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.
Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Clinical Applications of Mass Spectrometry track, ensuring a cost effective trip.
For more details, please visit http://selectbiosciences.com/conferences/index.aspx?conf=FAC2014
|28 Jun to 2 Jul 2015
Metabolomics 2015: 11th
Annual International Conference of the
Stay abreast of the latest Metabolomics Society news via the Twitter feed on the front page of the website (http://www.metabolomicssociety.org). Also you can follow us on Twitter: Metabolomics Society @MetabolomicsSoc and Metabolomics journal @Metabolomics. And you can visit us on Facebook.
Please come back later for detailed information about Metabolomics 2015 by visiting http://metabolomics2015.org.
This is a resource for
advertising positions in metabolomics. If you have a job
you would like posted in this newsletter, please email
Ian Forsythe (firstname.lastname@example.org).
Job postings will be carried for a maximum of 4
issues (8 weeks) unless the position is filled prior to
|Director of Computational Biology||Dynamic Biomarker Company||24-Feb-2014
|Metabolomics Faculty Position||Johns Hopkins University, School of Medicine||Baltimore, USA
|PhD CASE studentship in Development of metabolomics tools for clinical metabolomics||University of Birmingham||Birmingham, UK||13-Feb-2014||14-Mar-2014||Metabolomics Society|
|PhD CASE studentship in Development of metabolomics tools for environmental metabolomics||University of Birmingham||Birmingham, UK||13-Feb-2014||14-Mar-2014||Metabolomics Society|
|PhD in Identifying metabolomic contributions to disease mechanisms in dwarfisms caused by extracellular matrix gene defects||University of Manchester||Manchester, UK||3-Feb-2014||1-May-2014
||University of Manchester|
Ian J. Forsythe, M.Sc.MetaboNews
Department of Computing Science
University of Alberta
221 Athabasca Hall
Edmonton, AB, T6G 2E8, Canada
This newsletter is published in partnership between The Metabolomics Innovation Centre (TMIC, http://www.metabolomicscentre.ca/) and the Metabolomics Society (http://www.metabolomicssociety.org) for the benefit of the worldwide metabolomics community.
A single source destination for fee-for-service metabolic profiling including comprehensive metabolite identification, quantification, and analysis